SG11201606316XA - Methods of treating alzheimer's disease - Google Patents
Methods of treating alzheimer's diseaseInfo
- Publication number
- SG11201606316XA SG11201606316XA SG11201606316XA SG11201606316XA SG11201606316XA SG 11201606316X A SG11201606316X A SG 11201606316XA SG 11201606316X A SG11201606316X A SG 11201606316XA SG 11201606316X A SG11201606316X A SG 11201606316XA SG 11201606316X A SG11201606316X A SG 11201606316XA
- Authority
- SG
- Singapore
- Prior art keywords
- disease
- methods
- treating alzheimer
- alzheimer
- treating
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Immunology (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Genetics & Genomics (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Hospice & Palliative Care (AREA)
- Psychiatry (AREA)
- Mycology (AREA)
- Microbiology (AREA)
- Endocrinology (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Peptides Or Proteins (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Applications Claiming Priority (5)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201461937472P | 2014-02-08 | 2014-02-08 | |
US201461971479P | 2014-03-27 | 2014-03-27 | |
US201462010259P | 2014-06-10 | 2014-06-10 | |
US201462081992P | 2014-11-19 | 2014-11-19 | |
PCT/US2015/014758 WO2015120233A1 (fr) | 2014-02-08 | 2015-02-06 | Méthode de traitement de la maladie d'alzheimer |
Publications (1)
Publication Number | Publication Date |
---|---|
SG11201606316XA true SG11201606316XA (en) | 2016-08-30 |
Family
ID=52684643
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
SG10201913637RA SG10201913637RA (en) | 2014-02-08 | 2015-02-06 | Methods of treating alzheimer's disease |
SG11201606316XA SG11201606316XA (en) | 2014-02-08 | 2015-02-06 | Methods of treating alzheimer's disease |
Family Applications Before (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
SG10201913637RA SG10201913637RA (en) | 2014-02-08 | 2015-02-06 | Methods of treating alzheimer's disease |
Country Status (19)
Country | Link |
---|---|
US (3) | US20150246963A1 (fr) |
EP (2) | EP3102231B1 (fr) |
JP (4) | JP6685912B2 (fr) |
KR (4) | KR20210121288A (fr) |
CN (1) | CN106163548A (fr) |
AU (1) | AU2015214058B2 (fr) |
BR (1) | BR112016018170A2 (fr) |
CA (1) | CA2938466C (fr) |
CL (2) | CL2016001979A1 (fr) |
HK (1) | HK1231401A1 (fr) |
IL (1) | IL246999B (fr) |
MX (1) | MX2016010173A (fr) |
MY (1) | MY179105A (fr) |
NZ (1) | NZ723884A (fr) |
RU (1) | RU2724190C2 (fr) |
SG (2) | SG10201913637RA (fr) |
TW (1) | TWI705824B (fr) |
WO (1) | WO2015120233A1 (fr) |
ZA (1) | ZA201605341B (fr) |
Families Citing this family (15)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2015143447A2 (fr) * | 2014-03-21 | 2015-09-24 | Alzheon, Inc. | Méthodes de traitement de troubles neurologiques |
MA41115A (fr) | 2014-12-02 | 2017-10-10 | Biogen Int Neuroscience Gmbh | Procédé de traitement de la maladie d'alzheimer |
GB2541003A (en) * | 2015-08-05 | 2017-02-08 | Kran Life Sciences Llp | Neurodegenerative disorders |
KR102547164B1 (ko) * | 2015-09-10 | 2023-06-22 | 알제온, 인크. | 특정 환자 집단에서 신경퇴행성 장애를 치료하는 방법 |
EP4316512A3 (fr) * | 2015-10-28 | 2024-04-24 | The Trustees of The University of Pennsylvania | Administration intrathécale de vecteurs viraux adéno-associés pour la thérapie génique |
BR112018014762A2 (pt) * | 2016-01-20 | 2018-12-26 | Genentech Inc | método de tratamento da doença de alzheimer (da) precoce |
MA45149A (fr) * | 2016-06-07 | 2019-04-10 | Biogen Int Neuroscience Gmbh | Méthodes de traitement de la maladie d'alzheimer |
WO2018023036A1 (fr) * | 2016-07-29 | 2018-02-01 | Biogen Chesapeake Llc | Méthodes de traitement ou de prévention des anomalies, observées en imagerie, qui sont liées à l'immunisation contre l'amyloïde, associées au traitement de la maladie d'alzheimer |
IT201600118499A1 (it) * | 2016-11-25 | 2018-05-25 | Giacomo Koch | Uso di agonisti dopaminergici per la prevenzione della progressione della malattia di Alzheimer allo stadio precoce. |
US20200206220A1 (en) * | 2017-05-12 | 2020-07-02 | The Hong Kong University Of Science And Technology | Heterocyclic compounds as epha4 inhibitors |
SG11202001281WA (en) | 2017-08-22 | 2020-03-30 | Biogen Ma Inc | Pharmaceutical compositions containing anti-beta amyloid antibodies |
KR102224917B1 (ko) | 2018-03-20 | 2021-03-09 | (주)인벤티지랩 | 인지 장애 관련 질병의 예방 또는 치료용 약학적 조성물의 제조 방법 및 이의 제조 방법으로 제조된 인지 장애 관련 질병의 예방 또는 치료용 약학적 조성물 |
WO2019182319A1 (fr) * | 2018-03-20 | 2019-09-26 | (주)인벤티지랩 | Procédé de préparation de composition pharmaceutique de prévention ou de traitement de maladies associées au trouble cognitif, et composition pharmaceutique de prévention ou de traitement de maladies associées au trouble cognitif, préparée par le procédé de préparation |
BR112020020351A2 (pt) * | 2018-04-05 | 2021-01-12 | Calasia Pharmaceuticals, Inc. | Agentes farmacológicos para o tratamento de doenças oculares |
EP4373576A1 (fr) | 2021-07-22 | 2024-05-29 | Genentech, Inc. | Compositions ciblant le cerveau et leurs méthodes d'utilisation |
Family Cites Families (89)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4816567A (en) | 1983-04-08 | 1989-03-28 | Genentech, Inc. | Recombinant immunoglobin preparations |
US4737456A (en) | 1985-05-09 | 1988-04-12 | Syntex (U.S.A.) Inc. | Reducing interference in ligand-receptor binding assays |
US4676980A (en) | 1985-09-23 | 1987-06-30 | The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services | Target specific cross-linked heteroantibodies |
US6548640B1 (en) | 1986-03-27 | 2003-04-15 | Btg International Limited | Altered antibodies |
IL85035A0 (en) | 1987-01-08 | 1988-06-30 | Int Genetic Eng | Polynucleotide molecule,a chimeric antibody with specificity for human b cell surface antigen,a process for the preparation and methods utilizing the same |
DE3883899T3 (de) | 1987-03-18 | 1999-04-22 | Sb2, Inc., Danville, Calif. | Geänderte antikörper. |
DE68913658T3 (de) | 1988-11-11 | 2005-07-21 | Stratagene, La Jolla | Klonierung von Immunglobulin Sequenzen aus den variablen Domänen |
DE3920358A1 (de) | 1989-06-22 | 1991-01-17 | Behringwerke Ag | Bispezifische und oligospezifische, mono- und oligovalente antikoerperkonstrukte, ihre herstellung und verwendung |
US5959177A (en) | 1989-10-27 | 1999-09-28 | The Scripps Research Institute | Transgenic plants expressing assembled secretory antibodies |
US6075181A (en) | 1990-01-12 | 2000-06-13 | Abgenix, Inc. | Human antibodies derived from immunized xenomice |
US6150584A (en) | 1990-01-12 | 2000-11-21 | Abgenix, Inc. | Human antibodies derived from immunized xenomice |
US5770429A (en) | 1990-08-29 | 1998-06-23 | Genpharm International, Inc. | Transgenic non-human animals capable of producing heterologous antibodies |
ES2113940T3 (es) | 1990-12-03 | 1998-05-16 | Genentech Inc | Metodo de enriquecimiento para variantes de proteinas con propiedades de union alteradas. |
US5571894A (en) | 1991-02-05 | 1996-11-05 | Ciba-Geigy Corporation | Recombinant antibodies specific for a growth factor receptor |
DK0590058T3 (da) | 1991-06-14 | 2004-03-29 | Genentech Inc | Humaniseret heregulin-antistof |
GB9114948D0 (en) | 1991-07-11 | 1991-08-28 | Pfizer Ltd | Process for preparing sertraline intermediates |
EP0861893A3 (fr) | 1991-09-19 | 1999-11-10 | Genentech, Inc. | Expression de haut niveau d'immunoglobulines |
US5587458A (en) | 1991-10-07 | 1996-12-24 | Aronex Pharmaceuticals, Inc. | Anti-erbB-2 antibodies, combinations thereof, and therapeutic and diagnostic uses thereof |
WO1993008829A1 (fr) | 1991-11-04 | 1993-05-13 | The Regents Of The University Of California | Compositions induisant la destruction de cellules infectees par l'hiv |
EP0625200B1 (fr) | 1992-02-06 | 2005-05-11 | Chiron Corporation | Proteine de liaison biosynthetique pour marqueur de cancer |
AU691811B2 (en) | 1993-06-16 | 1998-05-28 | Celltech Therapeutics Limited | Antibodies |
US5789199A (en) | 1994-11-03 | 1998-08-04 | Genentech, Inc. | Process for bacterial production of polypeptides |
US5840523A (en) | 1995-03-01 | 1998-11-24 | Genetech, Inc. | Methods and compositions for secretion of heterologous polypeptides |
US5731168A (en) | 1995-03-01 | 1998-03-24 | Genentech, Inc. | Method for making heteromultimeric polypeptides |
US5869046A (en) | 1995-04-14 | 1999-02-09 | Genentech, Inc. | Altered polypeptides with increased half-life |
US6267958B1 (en) | 1995-07-27 | 2001-07-31 | Genentech, Inc. | Protein formulation |
GB9603256D0 (en) | 1996-02-16 | 1996-04-17 | Wellcome Found | Antibodies |
US6171586B1 (en) | 1997-06-13 | 2001-01-09 | Genentech, Inc. | Antibody formulation |
DE69830315T2 (de) | 1997-06-24 | 2006-02-02 | Genentech Inc., San Francisco | Galactosylierte glykoproteine enthaltende zusammensetzungen und verfahren zur deren herstellung |
US6040498A (en) | 1998-08-11 | 2000-03-21 | North Caroline State University | Genetically engineered duckweed |
ATE419009T1 (de) | 1997-10-31 | 2009-01-15 | Genentech Inc | Methoden und zusammensetzungen bestehend aus glykoprotein-glykoformen |
US6610833B1 (en) | 1997-11-24 | 2003-08-26 | The Institute For Human Genetics And Biochemistry | Monoclonal human natural antibodies |
JP4460155B2 (ja) | 1997-12-05 | 2010-05-12 | ザ・スクリプス・リサーチ・インステイチユート | マウス抗体のヒト化 |
ES2532910T3 (es) | 1998-04-02 | 2015-04-01 | Genentech, Inc. | Variantes de anticuerpos y fragmentos de los mismos |
US6194551B1 (en) | 1998-04-02 | 2001-02-27 | Genentech, Inc. | Polypeptide variants |
DK2180007T4 (da) | 1998-04-20 | 2017-11-27 | Roche Glycart Ag | Glycosyleringsteknik for antistoffer til forbedring af antistofafhængig cellecytotoxicitet |
US6737056B1 (en) | 1999-01-15 | 2004-05-18 | Genentech, Inc. | Polypeptide variants with altered effector function |
KR101077001B1 (ko) | 1999-01-15 | 2011-10-26 | 제넨테크, 인크. | 효과기 기능이 변화된 폴리펩티드 변이체 |
ES2571230T3 (es) | 1999-04-09 | 2016-05-24 | Kyowa Hakko Kirin Co Ltd | Procedimiento para controlar la actividad de una molécula inmunofuncional |
US7125978B1 (en) | 1999-10-04 | 2006-10-24 | Medicago Inc. | Promoter for regulating expression of foreign genes |
AU782626B2 (en) | 1999-10-04 | 2005-08-18 | Medicago Inc. | Method for regulating transcription of foreign genes |
CA2388245C (fr) | 1999-10-19 | 2012-01-10 | Tatsuya Ogawa | L'utilisation de cellules de rat adaptess exemptes de serum pour produire de polypeptides heterologues |
AU784983B2 (en) | 1999-12-15 | 2006-08-17 | Genentech Inc. | Shotgun scanning, a combinatorial method for mapping functional protein epitopes |
EP1272647B1 (fr) | 2000-04-11 | 2014-11-12 | Genentech, Inc. | Anticorps multivalents et leurs utilisations |
US7064191B2 (en) | 2000-10-06 | 2006-06-20 | Kyowa Hakko Kogyo Co., Ltd. | Process for purifying antibody |
EP2314686B2 (fr) | 2000-10-06 | 2023-06-21 | Kyowa Kirin Co., Ltd. | Cellules produisant une composition d'anticorps |
US6946292B2 (en) | 2000-10-06 | 2005-09-20 | Kyowa Hakko Kogyo Co., Ltd. | Cells producing antibody compositions with increased antibody dependent cytotoxic activity |
US6596541B2 (en) | 2000-10-31 | 2003-07-22 | Regeneron Pharmaceuticals, Inc. | Methods of modifying eukaryotic cells |
IL155977A0 (en) | 2000-11-30 | 2003-12-23 | Medarex Inc | Transgenic transchromosomal rodents for making human antibodies |
EP1423510A4 (fr) | 2001-08-03 | 2005-06-01 | Glycart Biotechnology Ag | Variants de glycosylation d'anticorps presentant une cytotoxicite cellulaire accrue dependante des anticorps |
HUP0600342A3 (en) | 2001-10-25 | 2011-03-28 | Genentech Inc | Glycoprotein compositions |
US20040093621A1 (en) | 2001-12-25 | 2004-05-13 | Kyowa Hakko Kogyo Co., Ltd | Antibody composition which specifically binds to CD20 |
CA2481657A1 (fr) | 2002-04-09 | 2003-10-16 | Kyowa Hakko Kogyo Co., Ltd. | Cellules a genome modifie |
WO2003084569A1 (fr) | 2002-04-09 | 2003-10-16 | Kyowa Hakko Kogyo Co., Ltd. | Medicament contenant une composition anticorps |
US20040132140A1 (en) | 2002-04-09 | 2004-07-08 | Kyowa Hakko Kogyo Co., Ltd. | Production process for antibody composition |
WO2003084570A1 (fr) | 2002-04-09 | 2003-10-16 | Kyowa Hakko Kogyo Co., Ltd. | Medicament contenant une composition d'anticorps appropriee au patient souffrant de polymorphisme fc$g(g)riiia |
US7749753B2 (en) | 2002-04-09 | 2010-07-06 | Kyowa Hakko Kirin Co., Ltd | Cells in which activity of the protein involved in transportation of GDP-fucose is reduced or lost |
US20040259150A1 (en) | 2002-04-09 | 2004-12-23 | Kyowa Hakko Kogyo Co., Ltd. | Method of enhancing of binding activity of antibody composition to Fcgamma receptor IIIa |
WO2003102157A2 (fr) | 2002-06-03 | 2003-12-11 | Genentech, Inc. | Bibliotheques de phages et anticorps synthetiques |
US7361740B2 (en) | 2002-10-15 | 2008-04-22 | Pdl Biopharma, Inc. | Alteration of FcRn binding affinities or serum half-lives of antibodies by mutagenesis |
EP1572744B1 (fr) | 2002-12-16 | 2010-06-09 | Genentech, Inc. | Variants d'immunoglobuline et utilisations |
WO2004065416A2 (fr) | 2003-01-16 | 2004-08-05 | Genentech, Inc. | Banques de phages anticorps synthetiques |
US20060104968A1 (en) | 2003-03-05 | 2006-05-18 | Halozyme, Inc. | Soluble glycosaminoglycanases and methods of preparing and using soluble glycosaminogly ycanases |
US7871607B2 (en) | 2003-03-05 | 2011-01-18 | Halozyme, Inc. | Soluble glycosaminoglycanases and methods of preparing and using soluble glycosaminoglycanases |
CA2542046A1 (fr) | 2003-10-08 | 2005-04-21 | Kyowa Hakko Kogyo Co., Ltd. | Composition proteique hybride |
EP1705251A4 (fr) | 2003-10-09 | 2009-10-28 | Kyowa Hakko Kirin Co Ltd | Procede permettant de produire une composition d'anticorps par inhibition par l'arn de la fonction de $g(a)1,6-fucosyltransferase |
ME01775B (fr) | 2003-11-05 | 2011-02-28 | Glycart Biotechnology Ag | Molecules fixatrices d'antigenes presentant une affinite de fixation du recepteur de fc et une fonction effectrice accrues |
WO2005053742A1 (fr) | 2003-12-04 | 2005-06-16 | Kyowa Hakko Kogyo Co., Ltd. | Medicament contenant une composition a base d'anticorps |
ZA200608130B (en) | 2004-03-31 | 2008-12-31 | Genentech Inc | Humanized anti-TGF-beta antibodies |
US7785903B2 (en) | 2004-04-09 | 2010-08-31 | Genentech, Inc. | Variable domain library and uses |
PT1737891E (pt) | 2004-04-13 | 2013-04-16 | Hoffmann La Roche | Anticorpos anti p-selectina |
TWI309240B (en) | 2004-09-17 | 2009-05-01 | Hoffmann La Roche | Anti-ox40l antibodies |
ES2579805T3 (es) | 2004-09-23 | 2016-08-16 | Genentech, Inc. | Anticuerpos y conjugados modificados por ingeniería genética con cisteína |
JO3000B1 (ar) | 2004-10-20 | 2016-09-05 | Genentech Inc | مركبات أجسام مضادة . |
US7625560B2 (en) * | 2004-12-15 | 2009-12-01 | Janssen Alzheimer Immunotherapy | Humanized antibodies that recognize beta amyloid peptide |
WO2007056441A2 (fr) | 2005-11-07 | 2007-05-18 | Genentech, Inc. | Polypeptides de liaison comprenant des sequences diversifiees et des sequences consensus hypervariables vh/vl |
CN102898519B (zh) * | 2005-11-30 | 2015-10-28 | Abbvie公司 | 抗淀粉样β蛋白的单克隆抗体及其用途 |
US20070237764A1 (en) | 2005-12-02 | 2007-10-11 | Genentech, Inc. | Binding polypeptides with restricted diversity sequences |
KR101505201B1 (ko) * | 2005-12-12 | 2015-03-24 | 에이씨 이뮨 에스.에이. | 치료적 특성을 갖는 베타 1-42 특이적인 단일클론성 항체 |
AR060871A1 (es) | 2006-05-09 | 2008-07-16 | Genentech Inc | Union de polipeptidos con supercontigos optimizados |
CL2007002070A1 (es) * | 2006-07-14 | 2008-02-08 | Ac Immune S A Genentech Inc | Anticuerpo quimerico o humanizado, o fragmentos de ellos, que se adhieren especificamente a por lo menos un epitopo en la proteina beta-amiloide; molecula de acido nucleico que lo codifica; composicion que lo comprende; su uso para tratar enfermedade |
DK2059533T3 (da) | 2006-08-30 | 2013-02-25 | Genentech Inc | Multispecifikke antistoffer |
US20080226635A1 (en) | 2006-12-22 | 2008-09-18 | Hans Koll | Antibodies against insulin-like growth factor I receptor and uses thereof |
CN100592373C (zh) | 2007-05-25 | 2010-02-24 | 群康科技(深圳)有限公司 | 液晶显示面板驱动装置及其驱动方法 |
JO3076B1 (ar) * | 2007-10-17 | 2017-03-15 | Janssen Alzheimer Immunotherap | نظم العلاج المناعي المعتمد على حالة apoe |
JP6157046B2 (ja) | 2008-01-07 | 2017-07-05 | アムジェン インコーポレイテッド | 静電的ステアリング(electrostaticsteering)効果を用いた抗体Fcヘテロ二量体分子を作製するための方法 |
TW201138807A (en) * | 2010-04-13 | 2011-11-16 | Baxter Int | Use of ventricular enlargement rate in intravenous immunoglobulin treatment of Alzheimer's disease |
NZ606357A (en) * | 2010-07-30 | 2015-05-29 | Genentech Inc | Safe and functional humanized anti beta-amyloid antibody |
JP2014001232A (ja) * | 2013-09-02 | 2014-01-09 | Janssen Alzheimer Immunotherapy | アミロイド原性疾患の処置 |
-
2015
- 2015-02-06 KR KR1020217030556A patent/KR20210121288A/ko active Application Filing
- 2015-02-06 MX MX2016010173A patent/MX2016010173A/es unknown
- 2015-02-06 TW TW104104180A patent/TWI705824B/zh active
- 2015-02-06 NZ NZ723884A patent/NZ723884A/en unknown
- 2015-02-06 CA CA2938466A patent/CA2938466C/fr active Active
- 2015-02-06 JP JP2016550529A patent/JP6685912B2/ja active Active
- 2015-02-06 KR KR1020247018360A patent/KR20240094017A/ko unknown
- 2015-02-06 EP EP15710295.5A patent/EP3102231B1/fr active Active
- 2015-02-06 AU AU2015214058A patent/AU2015214058B2/en active Active
- 2015-02-06 RU RU2016136081A patent/RU2724190C2/ru active
- 2015-02-06 WO PCT/US2015/014758 patent/WO2015120233A1/fr active Application Filing
- 2015-02-06 KR KR1020237013210A patent/KR20230056800A/ko not_active Application Discontinuation
- 2015-02-06 BR BR112016018170-0A patent/BR112016018170A2/pt not_active Application Discontinuation
- 2015-02-06 CN CN201580017492.8A patent/CN106163548A/zh active Pending
- 2015-02-06 US US14/616,261 patent/US20150246963A1/en not_active Abandoned
- 2015-02-06 EP EP19188687.8A patent/EP3718563A1/fr not_active Withdrawn
- 2015-02-06 SG SG10201913637RA patent/SG10201913637RA/en unknown
- 2015-02-06 KR KR1020167024829A patent/KR20160111039A/ko not_active Application Discontinuation
- 2015-02-06 MY MYPI2016702789A patent/MY179105A/en unknown
- 2015-02-06 SG SG11201606316XA patent/SG11201606316XA/en unknown
-
2016
- 2016-07-28 IL IL246999A patent/IL246999B/en active IP Right Grant
- 2016-08-02 ZA ZA2016/05341A patent/ZA201605341B/en unknown
- 2016-08-05 CL CL2016001979A patent/CL2016001979A1/es unknown
-
2017
- 2017-05-22 HK HK17105176.6A patent/HK1231401A1/zh unknown
- 2017-11-03 CL CL2017002781A patent/CL2017002781A1/es unknown
-
2019
- 2019-12-20 JP JP2019230200A patent/JP2020073507A/ja active Pending
-
2020
- 2020-02-05 US US16/782,654 patent/US20200399352A1/en not_active Abandoned
-
2021
- 2021-08-04 US US17/394,053 patent/US20220195020A1/en not_active Abandoned
- 2021-12-17 JP JP2021204857A patent/JP2022058369A/ja not_active Withdrawn
-
2023
- 2023-12-14 JP JP2023210860A patent/JP2024037893A/ja active Pending
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
IL285722A (en) | Methods for treating Alzheimer's disease | |
IL247085A0 (en) | Methods for treating Alzheimer's disease | |
ZA201605341B (en) | Methods of treating alzheimer's disease | |
IL276315A (en) | Donepezil preparations and a method for treating Alzheimer's disease | |
SG11201701723XA (en) | Methods of treating liver disease | |
GB201701673D0 (en) | Methods of well treatment | |
IL263433A (en) | Methods for treating Alzheimer's disease | |
HK1245127A1 (zh) | 治療腦疾病的方法和組合物 | |
HK1258994A1 (zh) | 用於疾病治療的方法 | |
HK1243709A1 (zh) | 可用於治療阿爾茨海默氏病的四氫呋喃稠合的氨基氫噻嗪衍生物 | |
EP3137097C0 (fr) | Traitement et prévention de la maladie d'alzheimer | |
HK1246271A1 (zh) | 用於合成羥基-三甘油酯的方法及其用於預防和治療疾病的用途 | |
HK1243937A1 (zh) | 治療疾病的方法 | |
PL3137093T3 (pl) | Leczenie i profilaktyka choroby Alzheimera (AD) | |
PL3137094T3 (pl) | Leczenie i profilaktyka choroby alzheimera (ad) | |
HK1245081A1 (zh) | 用於治療阿爾茨海默病的方法 | |
GB201511453D0 (en) | Treatment of alzheimer's disease | |
GB201621398D0 (en) | Treatment of emt-associated disease | |
GB201504144D0 (en) | Treatment of Parkinson's disease | |
GB201414038D0 (en) | Alzheimer's disease | |
GB201504413D0 (en) | Treatment of disease |